NSCLC (NON-SMALL CELL LUNG CANCER)

This study tests a new drug called OSE-279 that blocks PD-1, a protein that can stop the immune system from attacking cancer. It is for people with advanced solid tumors or lymphomas that have not responded to other treatments. The study has three parts: first finding a safe dose…

This early-stage study tests a new drug called XB010, alone or with another drug (pembrolizumab), in people with advanced solid tumors that have not responded to other treatments. The main goals are to find the safest dose and check for side effects. About 396 adults with cancers…

This study tests a combination of microwave ablation (a heat-based tumor destruction technique) plus two drugs (tislelizumab and docetaxel) in 20 adults with advanced non-small cell lung cancer that worsened after initial immunotherapy and chemotherapy. The goal is to see if this…

This early-phase trial tests an experimental drug called IAM1363 in people with advanced cancers that have HER2 alterations. The study aims to find a safe dose and see if the drug can shrink tumors, including those that have spread to the brain. About 383 adults whose cancer has …

This study tests a new treatment for people with advanced non-small cell lung cancer that no longer responds to PD-1 inhibitors. The treatment combines special immune cells (WAST cells) with a chemotherapy drug called docetaxel. The goal is to see if this combination can shrink t…

This study tests a new drug called YH42946 in people with advanced solid tumors that have certain genetic changes (HER2 or EGFR). The goal is to see if the drug is safe, how the body processes it, and whether it can shrink tumors. About 161 participants will receive the drug, and…

This study is for people with stage II-IIIB non-small cell lung cancer who had surgery after initial chemotherapy and immunotherapy but still had some cancer cells left. Researchers want to see if using a sensitive blood test (MRD) to guide additional treatment with the immunothe…

This study tests a new drug called PC14586 (rezatapopt) in people with advanced or spreading solid tumors that have a specific change in the TP53 gene (Y220C mutation). The goal is to see if the drug is safe and works against these cancers. About 300 adults (and some teens after …

This study tests whether taking ensartinib pills along with standard chemotherapy before surgery can help shrink tumors in people with ALK-positive non-small cell lung cancer. About 20 adults with stage II to IIIB cancer will receive the treatment for 9 weeks, then have surgery. …

This study is testing whether a new device called CAROL is safe for treating small lung tumors (≤2 cm) in people with non-small cell lung cancer. Seven adults who are already scheduled for surgery will receive the device during their procedure. The main goal is to check for side …

This early-phase study tests a new drug called TGI-5, either alone or combined with the immunotherapy nivolumab, in people with advanced solid tumors (colorectal, melanoma, liver, or lung cancer) that cannot be removed by surgery. The main goals are to check safety and find the r…

This early-stage study tests a new drug called EPI-326 in about 110 people with advanced lung cancer (with a specific EGFR gene change) or head and neck cancer. The main goal is to find a safe dose and check for side effects. Researchers will also measure drug levels in the blood…

This study tests a new treatment called A2B395 for adults with advanced solid tumors (like colorectal, lung, breast, and kidney cancers) that have not responded to standard therapy. The treatment uses specially engineered immune cells designed to kill cancer cells while protectin…

This early-stage trial tests a new drug called GV20-0251 in people with advanced solid tumors that no longer respond to standard treatments. The main goal is to check the drug's safety. About 10 adults with cancers like liver, lung, or skin cancer will take part. This is not a cu…

This early-phase study tests a new drug called ALTA3263 in adults with advanced solid tumors (like pancreatic, lung, or colorectal cancer) that have a specific KRAS gene mutation. The main goals are to check safety and find the right dose. About 188 people who have tried other tr…

This study tests a new oral drug, RMC-6236, against standard chemotherapy (docetaxel) in people with advanced non-small cell lung cancer that has a specific RAS mutation and has already been treated with immunotherapy and platinum chemo. About 420 adults will be randomly assigned…

This early-phase study tests a new treatment called 177LuBetaBart for people with advanced solid tumors that have stopped responding to standard therapies. The treatment combines a targeting antibody with a radioactive particle to deliver radiation directly to cancer cells. The s…

This early-stage study tests a new drug, NXP900, in about 140 adults with advanced solid tumors (like lung, kidney, or mesothelioma) that have not responded to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. Participants will receive NX…

This study tests a new experimental drug (PF-07799544) combined with another drug (PF-07799933) in adults with advanced solid tumors that have a specific gene change called BRAF V600. The goal is to see if the combination is safe and can shrink or control the cancer. Participants…

This study follows 190 people with inoperable lung cancer or limited lung metastases who receive a single, high-dose radiation treatment. Researchers track quality of life using detailed questionnaires before treatment and at several points over a year. The goal is to understand …

This study collects live tumor tissue from 2,000 people with various cancers to understand why some respond to immunotherapy and others don't. Participants give a biopsy as part of their normal care, and researchers analyze the samples in the lab. The goal is to develop better wa…